Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data

Pembrolizumab is a full-length human immunoglobulin G4 (IgG4) monoclonal antibody directed against the immune checkpoint PD-1 to remove its binding with PD-L1 and thus to restore an anti-tumor immune response of T cells. Pembrolizumab is one of the most advanced immune checkpoint inhibitors for canc...

Descripción completa

Detalles Bibliográficos
Autores principales: du Rusquec, Pauline, de Calbiac, Ombline, Robert, Marie, Campone, Mario, Frenel, Jean Sebastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527794/
https://www.ncbi.nlm.nih.gov/pubmed/31190995
http://dx.doi.org/10.2147/CMAR.S151023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527794/
https://www.ncbi.nlm.nih.gov/pubmed/31190995
http://dx.doi.org/10.2147/CMAR.S151023

Ejemplares similares